医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ニュース
添付文書
薬の臨床実感＆助言集

ENHERTU

ENHERTU® Approved in the EU as the First HER2 Directed Therapy for Patients with HER2 Low Metastatic Breast Cancer

その他ヘルスバイオテクノロジーヘルスケア外科腫瘍学製薬　 TimeLine: ENHERTU

2023年01月26日

ENHERTU® Recommended for Approval in the EU by CHMP for Patients with HER2 Low Metastatic Breast Cancer

バイオテクノロジーヘルスケア腫瘍学製薬　 TimeLine: ENHERTU

2022年12月19日

ENHERTU® Approved in the EU for Patients with Previously Treated HER2 Positive Advanced Gastric Cancer

ヘルスケア腫瘍学製薬　 TimeLine: ENHERTU

2022年12月19日

ENHERTU® Achieved Statistically Significant Overall Survival Reducing the Risk of Death by 36% Versus Trastuzumab Emtansine (T-DM1) in Patients with HER2 Positive Metastatic Breast Cancer in DESTINY-Breast03

ヘルスケアヘルス一般腫瘍学臨床試験　 TimeLine: Achieved Statistically Significant Overall Survival Reducing the ENHERTU in Patients with HER2 Positive Metastatic Breast Cancer in DESTINY-Breast03 T-DM

2022年12月07日

ENHERTU® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Advanced Gastric Cancer

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: ENHERTU

2022年11月14日

ENHERTU® Continues to Demonstrate Clinically Meaningful Tumor Response in Patients with HER2 Mutant Metastatic Non-Small Cell Lung Cancer

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: Continues to Demonstrate Clinically Meaningful Tumor Response in Patients with HER2 Mutant Metastatic Non-Small Cell Lung Cancer ENHERTU

2022年09月11日

ENHERTU® Significantly Delayed Disease Progression in DESTINY-Breast02 Phase 3 Trial Versus Physician’s Choice of Treatment in Patients with HER2 Positive Metastatic Breast Cancer

ENHERTU® Significantly Delayed Disease Progression in DESTINY-Breast02 Phase 3 Trial Versus Physician’s Choice of Treatment in Patients with HER2 Positive Metastatic Breast Cancer

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: ENHERTU Significantly Delayed Disease Progression in DESTINY-Breast02 Phase Trial Versus Physician’s Choice of Treatment in Patients with HER2 Positive Metastatic Breast Cancer

2022年08月15日

ENHERTU® Approved in the U.S. as the First HER2 Directed Therapy for Patients with Previously Treated HER2 Mutant Metastatic Non-Small Cell Lung Cancer

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: as the First HER2 Directed Therapy for Patients with Previously Treated HER2 Mutant Metastatic Non-Small Cell Lung Cancer ENHERTU

2022年08月12日

ENHERTU® Granted Priority Review in the U.S. for Patients with HER2 Low Metastatic Breast Cancer

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: ENHERTU Granted Priority Review

2022年07月25日

ENHERTU® Approved in the EU for Patients with HER2 Positive Metastatic Breast Cancer Treated with One or More Prior Anti-HER2-Based Regimens

ヘルスケア腫瘍学臨床試験製薬　 TimeLine: ENHERTU EU for Patients with HER2 Positive Metastatic Breast Cancer Treated with One or More Prior Anti-HER2-Based Regimens

2022年07月19日